Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness - Gilde Healthcare

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiv...

20 mei 2022
London (UK) & Utrecht (the Netherlands)
Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds a new era in digital medicine.

The NICE guidance states that Sleepio, Big Health’s digital therapeutic for insomnia, is a safe and effective treatment for people who would otherwise only have access to the current standard of care, which includes sleep hygiene advice and medication. In addition, NICE confirms Sleepio as cost-saving for the National Health Service (NHS), with evidence showing Sleepio reduces GP appointments and prescribing costs by providing instant access to cognitive behavioural therapy for insomnia (CBT-I) where face-to-face CBT-I is unavailable.

Studies show that nearly one-third of adults in the United Kingdom (UK) experience insomnia symptoms each week. NICE recommends CBT-I as the first-line treatment for insomnia, offered before or alongside medication. However, due to a lack of trained therapists, CBT-I is unfortunately not routinely available in the NHS for most people living with insomnia.

The NICE Medical Technologies Advisory Committee evaluated Sleepio’s industry-leading evidence base of 28 studies including 12 randomised controlled trials, featuring thousands of patients who had a diagnosis or symptoms of insomnia. Peer-reviewed clinical trials show Sleepio helps 76% of patients to achieve clinical improvement in insomnia. The Committee concluded that Sleepio is more effective than treatment as usual (sleep hygiene and medication) in reducing symptoms of insomnia in adults and is a cost-saving option, as demonstrated by an independent health economic evaluation of NHS services in the Thames Valley.

“This is a significant moment for the NHS and UK healthcare innovation as a whole,” said Dr. Nick Broughton, CEO of Oxford Health NHS Foundation Trust and Board Member of the Oxford Academic Health and Science Network (AHSN). “Sleepio has the potential to transform current mental health pathways by expanding access to guideline-recommended care for everyone in England. The Oxford AHSN and Oxford Health are delighted to have played a key role in Sleepio’s flagship implementation in the Thames Valley, where Innovate UK funding helped generate rich real-world evidence that made NICE’s evaluation possible. We hope that Sleepio will now be made available across the country.”

Sleepio is a clinically-evidenced digital therapeutic for insomnia developed by world-renowned clinical psychologist and sleep expert Professor Colin Espie. The programme is fully automated and highly personalised, with an algorithm tailoring behavioural interventions including CBT to each individual’s symptoms and needs. It is accessed via smartphone or web browser, meaning people can engage with Sleepio wherever and whenever they wish, without the need for clinician involvement. NICE guidance is a key step in increasing patient access to Sleepio, since it gives NHS commissioners and clinicians added confidence in funding and prescribing Sleepio to their populations.

About Big Health
Big Health’s mission is to help millions back to good mental health by providing safe and effective non-drug alternatives for the most common mental health conditions. Designed by leading clinical experts and backed by 13 RCTs, Sleepio™ for insomnia and Daylight™ for worry and anxiety are among the world’s most evidenced digital mental health solutions. These programmes seamlessly integrate into primary care, enabling clinically effective self-management of mental health. With offices in London and San Francisco, Big Health’s digital therapeutics are used by leading health systems like the NHS and large multinational employers. For more information, please visit www.bighealth.co.uk

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.9 billion ($ 2.0 billion) across two fund strategies: Venture&Growth and Private Equity. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in healthtech, medtech and therapeutics in Europe and North America. Further information at www.gildehealthcare.com

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
20 mei 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
19 mei 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding...
4 mei 2022